期刊文献+

建立前列腺特异性抗原灰区患者重复穿刺阳性的数学模型 被引量:1

Establishment of a nomogram for predicting positive repeat prostate biopsy in patients with total PSA 4 to 10 ng/ml
原文传递
导出
摘要 目的:建立预测前列腺特异性抗原(PSA)灰区患者重复穿刺阳性的数学模型。方法:选择2004~2016年158例血清PSA位于4~10ng/ml且首次穿刺病理结果为阴性的患者行重复穿刺,记录并分析患者的年龄、前列腺体积(PV)、PSA、游离PSA(fPSA)/总PSA(tPSA)、前列腺特异性抗原速率(PSAV)、前列腺特异抗原密度(PSAD)、前列腺移行带特异性抗原密度(PSAD-TZ)、超声检查(TRUS)、直肠指检(DRE)、高级别上皮内瘤变(HGPIN)、不典型小腺泡增生(ASAP)等重复活检结果的潜在预测指标。将有统计学意义的变量行二分类Logistic回归分析和建立数学模型,该模型的预测价值通过ROC曲线下面积(AUC)来评估。结果:158例前列腺重复穿刺活检患者中,前列腺癌的检出率为25.9%(41/158),单变量分析结果中统计学上有意义的指标包括Age、PV、f/tPSA、PSAD、PSAD-TZ、DRE、TRUS、Previous HGPIN、Previous ASAP(P<0.05),对以上所有变量进行二分类Logistic回归分析并建立数学模型,预测指标ASAP、HGPIN、f/tPSA、TRUS、DRE被纳入该模型。该模型AUC为89.8%,预测价值较高。结论:该数学模型可以很好的预测PSA患者重复穿刺阳性的概率,能够帮助临床医师判断哪些PSA灰区患者更适合行超声引导下前列腺重复穿刺活检术。 Objective:To establish a nomogram to predict the outcome of a repeat prostate biopsy in patients with serum total prostate-specific antigen(PSA)4 to 10 ng/ml.Method:From 2004 to 2016,158 patients with total PSA 4 to 10 ng/ml underwent repeat prostate biopsy.Potential predictors as age,prostate volume(PV),total PSA(tPSA),free-to-total PSA(f/tPSA),PSA velocity(PSAV),PSA density(PSAD),PSA transitional zone density(PSAD-TZ),transrectal ultrasound(TRUS),digital rectal examination(DRE),high-grade intraepithelial neoplasia(HGPIN),atypical small acinar proliferation(ASAP)were obtained and subjected to univariate analysis.Then we entered the significant variables stepwise into logistic regression models,and developed a nomogram on the probability of prostate cancer in repeat biopsy,whose predictive value was evaluated by receiver operating characteristic(ROC)analysis.Result:Forty-one(25.9%)patients were diagnosed with prostate cancer.Of all the potential predictors,age,PV,f/tPSA,PSAD,PSAD-TZ,TRUS,DRE,HGPIN,ASAP were significantly statistical difference in univariate analysis.On a series of analysis,ASAP,HGPIN,f/tPSA,TRUS,DRE were included in the predictive nomogram.The nomogram exhibited a high predictive value,with the area under the ROC curve(AUC)of 89.8%,significantly greater than that of the prediction based single predictor.Conclusion:The nomogram is a valuable multi-variable predictive tool,which can be used by urologists to aid decisionmaking for patients with total PSA 4 to 10 ng/ml for whom a repeat biopsy is being considered.
出处 《临床泌尿外科杂志》 2018年第2期137-140,共4页 Journal of Clinical Urology
关键词 前列腺癌 重复穿刺 数学模型 prostate cancer repeat biopsy nomogram
  • 相关文献

参考文献1

二级参考文献29

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA CancerJ Clin 2013; 63:11-30.
  • 2US Preventive Services Task Force. Screening for prostate cancer: draft recommentation statement. Rockville, MD: US Preventive Services Task Force; 2001. http://www. uspreventiveservicestaskforceorg/uspstf 12/prostate/draftrec prostate.ht m.
  • 3Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002; 60: 115-9.
  • 4Labrie F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol2011; 8: 73-85.
  • 5Labrie F, Dupont A, Belanger A, Giguere M, Lacourciere Y eta/. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem 1985; 23: 833-41.
  • 6Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R eta/. A controlled trial of ieuprolide with and without flutamide in prostatic carcinoma. N Engi J Med 1989; 321: 419-24.
  • 7Denis L J, Keuppens F, Smith PH, Whelan P, Carneiro de Moura JL et a/. Maximal androgen blockade: final analysis of EORTC Phase Ill tria/30853. Eur Uro/1998; 33: 144-51.
  • 8Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa Set al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Uro12006; 176: S47-9.
  • 9Ueno S, Namiki M, Fukagai T, Ehara H, Usami Metal. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006; 13: 1494-500.
  • 10Labrie F, Dupont A, Suburu R, Cusan L, Tremblay Met al. Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J Urol 1992; 147:846 52.

共引文献1

同被引文献1

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部